Last update Jan. 15, 2023


Likely Compatibility

Fairly safe. Mild or unlikely adverse effects. Compatible under certain circumstances. Follow-up recommended. Read Commentary.

It is an anticholinergic and antispasmotic agent, acetylcholine M3 muscarinic receptor blocker with atropine-like actions, used to treat urinary frequency, urgency, and incontinence and overactive bladder syndrome. Oral administration once a day.

At the date of the last update we did not find any published data on its excretion in breast milk.

Its pharmacokinetic data (large volume of distribution and high percentage of protein binding), make it unlikely that significant quantities will be transferred to breastmilk.

Its very low oral bioavailability hinders transfer to infant plasma from breastmilk, except in premature infants and the immediate neonatal period when there may be greater intestinal permeability.

Milk production should be monitored, since anticholinergics can reduce milk production.

Possible anticholinergic symptoms (dry mouth, constipation...) in the infant should be monitored.

Until more published data is known about this drug in relation to breastfeeding, known safer alternatives are preferable, especially during the neonatal period and in the event of prematurity.


  • Oxybutynin (Fairly safe. Mild or unlikely adverse effects. Compatible under certain circumstances. Follow-up recommended. Read Commentary.)

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

Darifenacin in other languages or writings:


Main tradenames from several countries containing Darifenacin in its composition:


Variable Value Unit
Oral Bioavail. 15 - 19 %
Molecular weight 427 daltons
Protein Binding 98 %
VD 2.3 l/Kg
pKa 16.2 -
Tmax 6.5 hours
13 - 19 hours


  1. Merus. Darifenacin. Drug Summary. 2013 Full text (in our servers)
  2. Novartis. Darifenacin. Drug Summary. 2008 Full text (in our servers)

Total visits


Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at

e-lactancia is a resource recommended by El Parto Es Nuestro of Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM